Novo Nordisk a star amid stodgy pharmaceuticals By: MarketWatch May 17, 2010 at 04:59 AM EDT While the large-cap pharmaceuticals struggle, Novo Nordisk has rallied as its expertise in diabetes pays off. Some say the advance has run too far. Read More >> Related Stocks: Eli Lilly Gsk Plc ADR Merck & Co Novo Nordisk A/S ADR Sanofi-Aventis S.A. ADR